Life sciences company Malin will invest up to $30m in the series A round closed by Poseida Therapeutics, which is working on liver disease and cancer treatments.
Poseida Therapeutics, a US-based startup developing drugs based on its genome engineering technologies, has closed a series A round in which life sciences company Malin Corporation will invest up to $30m.
The other investors in the round were not named. Poseida will use the capital to accelerate a therapeutics pipeline that includes gene therapies being developed to treat orphan liver diseases as well as autologous chimeric antigen receptor T-cell treatments for cancer.
Kelly Martin, chief executive of Ireland-based Malin, and…
